INDV Indivior Pharmaceuticals Inc

QT69

NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·USA

Latest market price

36.28

+0.91+2.57%

Overview Short InterestFilings

INDVQT69Indivior Pharmaceuticals Inc·NASDAQ

Overview Short InterestFilings

36.28+2.57%

Filing

Up 2.6% — Filed an 8-K material-event report (2026-11-02) — details in the filing.

Medium confidence

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AMRX-4.97%$20.44 LNTH-0.15%$100.31 RGC-6.26%$6.29 BHC-2.20%$8.02 ALKS-0.99%$44.89 SUPN+0.19%$41.92 HCM+0.91%$13.27 PRGO-0.19%$15.75

Snapshot

Index	—	P/E	10.13	EPS (ttm)	3.58	Insider Own	1.86%	Shs Outstand	124.77M	Perf Week	4.98%

Market Cap	4.53B	Forward P/E	8.36	EPS next Y	4.34	Insider Trans	-3.02%	Shs Float	109.45M	Perf Month	1.60%

Enterprise Value	4.72B	PEG	1.34	EPS next Q	0.99			Short Float	8.60%	Perf Quarter	-0.60%

Income	450.00M	P/S	3.29	EPS this Y	71.87%			Short Ratio	4.14	Perf Half Y	-6.93%

Sales	1.37B	P/B	—	EPS next Y	7.27%	ROA	33.78%	Short Interest	9.41M	Perf YTD	1.11%

Book/sh	-0.48	P/C	14.84	EPS next 5Y	7.55%	ROE	—	52W High	42.81 -15.25%	Perf Year	24.55%

Cash/sh	2.44	P/FCF	146.02	EPS past 3/5Y	—	ROIC	95.41%	52W Low	27.68 31.07%	Perf 3Y	83.23%

Dividend Est.	—	EV/EBITDA	8.30	Sales past 3/5Y	11.20% 13.88%	Gross Margin	85.15%	Volatility	4.55% 3.59%	Perf 5Y	119.21%

Dividend TTM	—	EV/Sales	3.43	EPS Y/Y TTM	175.38%	Oper. Margin	43.67%	ATR (14)	1.26	Perf 10Y	90.45%

Dividend Ex-Date	Nov 03, 2026	Quick Ratio	0.50	Sales Y/Y TTM	16.34%	Profit Margin	32.75%	RSI (14)	58.42	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	0.61	EPS Q/Q	83.33%	SMA20	3.78%	Beta	1.12	Target Price	48.00

Payout	0.00%	Debt/Eq	—	Sales Q/Q	13.38%	SMA50	3.11%	Rel Volume	1.57	Prev Close	35.37

Employees	833	LT Debt/Eq	—	Earnings	Feb 25	SMA200	1.68%	Avg Volume	2.33M	Price	36.28

IPO Date	Dec 29, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	24.45% 8.09%	Net Debt/EBITDA	0.33	Volume	3,646,215	Change	2.57%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-05-26	Reiterated	Barclays	Overweight	$46 → $43
Aug-04-26	Reiterated	Craig-Hallum	Buy	$50 → $53
Jun-18-26	Initiated	Barclays	Overweight	$46
Jan-20-26	Reiterated	Northland Securities		$40 → $50
Jan-12-26	Reiterated	HC Wainwright & Co.	Buy	$35 → $48
Dec-03-25	Reiterated	Morgan Stanley		$28 → $36
Oct-31-25	Reiterated	Craig-Hallum	Buy	$34 → $41
Oct-31-25	Reiterated	Northland Securities		$30 → $40
Oct-30-25	Reiterated	HC Wainwright & Co.	Buy	$35
Aug-27-25	Reiterated	Craig-Hallum	Buy	$20 → $34

Latest News· Times ET

Nov-02-26

Nov-02-2604:43PM

Why Indivior Pharmaceuticals Stock Topped the Market Todayfool.com

Oct-29-26

Oct-29-2607:00AM

Indivior Reports Third Quarter 2026 Financial Resultsglobenewswire.com

03:01AM

Indivior Pharmaceuticals Affirms FY2026 Sales Guidance of $1.295B-$1.365B vs $1.334B EstBenzinga

Oct-22-26

Oct-22-2606:08PM

MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600Yahoo

02:41AM

Indivior (INDV) Projected to Announce Earnings on Thursdaydefenseworld.net

Oct-19-26

Oct-19-2608:30AM

Indivior to Report Third Quarter 2026 Financial Resultsglobenewswire.com

Oct-18-26

Oct-18-2602:15AM

Indivior PLC (NASDAQ:INDV) Stock Has Average Price Target of $45.17defenseworld.net

Oct-14-26

Oct-14-2605:56AM

Indivior: Sublocade Growth And Improving Profitability Create Upside PotentialSeekingAlpha

Sep-25-26

Sep-25-2604:15AM

Financial Contrast: Sonoma Pharmaceuticals (NASDAQ:SNOA) versus Indivior (NASDAQ:INDV)defenseworld.net

Sep-24-26

Sep-24-2605:16PM

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPNbusinesswire.com

Sep-17-26

Sep-17-2607:00AM

Indivior Pharmaceuticals, Inc. Declares Special Cash DividendYahoo

Sep-14-26

Sep-14-2609:30AM

5 Small Drug Stocks Poised to Benefit From a Biotech RecoveryYahoo

Sep-12-26

Sep-12-2603:39AM

HighTower Advisors LLC Makes New $3.41 Million Investment in Indivior PLC $INDVdefenseworld.net

Sep-02-26

Sep-02-2611:30AM

Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?Yahoo

Aug-29-26

Aug-29-2608:00AM

INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholdersgurufocus.com

Company

Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	1,374	1,239	1,188	1,093	—	—	—	—	—
Cost of Goods Sold Incl. D&A	204	246	231	174	—	—	—	—	—
Gross Profit	1,170	993	957	919	—	—	—	—	—
Selling, General and Administrative Excl. Other	520	634	618	569	—	—	—	—	—
Research and Development	50	97	107	116	—	—	—	—	—
Other Operating Expense	0	-3	200	390	—	—	—	—	—
Operating Income	600	265	32	-156	—	—	—	—	—
Interest Expense	17	45	41	35	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-45	19	23	42	—	—	—	—	—
Net Income Before Taxes	538	239	14	-149	—	—	—	—	—
Income Taxes	88	29	11	-20	—	—	—	—	—
Consolidated Net Income	450	210	2	-129	—	—	—	—	—
Net Income From Continuing Operations	450	210	3	-129	—	—	—	—	—
Net Income	450	210	2	-129	—	—	—	—	—
EPS (Recurring)	3.66	1.68	0.02	-0.94	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	3.66	1.68	0.02	-0.94	—	—	—	—	—
EPS (Diluted)	3.58	1.64	0.02	-0.91	—	—	—	—	—
EBITDA	568	304	83	-99	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	10.13	21.88	828.67	—	—	—	—	—	—
Price To Sales Ratio	3.12	3.62	1.38	1.91	—	—	—	—	—
Gross Margin	85.15	80.15	80.56	84.08	—	—	—	—	—
Operating Margin	43.67	21.39	2.69	-14.27	—	—	—	—	—
Net Margin	32.75	16.95	0.17	-11.80	—	—	—	—	—
Shares Outstanding	118	125	132	137	—	—	—	—	—
Market Capitalization	4,281	4,485	1,641	2,092	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anderson Woodrow D	Chief Accounting Officer	Aug 27 '26	Buy	35.69	1,500	53,535	27,638	Aug 27
Anderson Woodrow D	Chief Accounting Officer	Aug 05 '26	Buy	36.28	1,500	54,420	26,138	Aug 05
Heidbreder Christian	Chief Scientific Officer	Jul 10 '26	Sale	41.14	18,586	764,628	209,337	Jul 13
Ciaffoni Joseph	Chief Executive Officer	Jun 22 '26	Option Exercise	0.00	1,266,903	0	1,402,879	Jun 23
Heidbreder Christian	Chief Scientific Officer	Jun 11 '26	Sale	38.06	18,586	707,383	227,923	Jun 12
Preblick Ryan	Chief Financial Officer	Jun 08 '26	Sale	37.70	36,000	1,357,200	284,751	Jun 10
Preblick Ryan	Chief Financial Officer	Mar 14 '26	Option Exercise	0.00	6,302	0	323,594	Mar 17
Ryan Barbara	Director	Mar 13 '26	Buy	31.09	8	249	5,724	Mar 13
Ryan Barbara	Director	Mar 09 '26	Buy	32.56	31	1,009	5,716	Mar 11
Kingsley Stuart A	Director	Mar 06 '26	Buy	31.86	940	29,953	5,582	Mar 11
Anderson Woodrow D	Chief Accounting Officer	Mar 03 '26	Option Exercise	0.00	48,285	0	29,657	Mar 05
Preblick Ryan	Chief Financial Officer	Mar 03 '26	Option Exercise	0.00	200,459	0	317,292	Mar 05
Burris Jeffrey W	Chief Legal Officer	Mar 03 '26	Option Exercise	0.00	184,193	0	107,550	Mar 05
Heidbreder Christian	Chief Scientific Officer	Mar 03 '26	Option Exercise	0.00	234,109	0	292,306	Mar 05
Ryan Barbara	Director	Jan 05 '26	Buy	35.39	775	27,429	1,963	Jan 07

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.